HLA class I genes influence the rate of disease progression [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Homozygosity at any class I locus is associated with more rapid disease progression during untreated infection [10, 11] , likely because homozygosity may limit the ability of the immune system to respond to a diverse range of peptide antigens [14] , allowing HIV to more easily escape the immune response [11] . Similarly, a hypothesis of "frequency-dependent selection" postulates that, on a population basis, the virus adapts to the most commonly encountered HLA-restricted immune responses, conferring a selective advantage on individuals expressing rare alleles [12, 13] . In addition, several specific alleles-most notably, those at the HLA-B locus [15] -are associated with the risk of progression of HIV disease [3] [4] [5] [6] [7] [8] [9] : HLA-B*5701 and B*27 are associated with protective effects [4] at different stages in the natural history of the disease [16] , whereas HLA-B*35P(x) (comprising B*3502, B*3503, B*3504, and B*5301) [17] and the B22 serogroup (com-prising B*54, B*55, and B*56) [5] are associated with accelerated disease progression.
Although a complete understanding of the contributions of HLA diversity to HIV disease has by no means been achieved, an area of equal interest has now emerged: the relevance of HLA genetic diversity in the era of highly active antiretroviral therapy (HAART). Although the introduction of HAART in the mid-1990s completely changed the clinical course of HIV infection among treated individuals, a wide range of interindividual differences in treatment responses continues to be observed. Because consistent evidence suggests that host genetic factors significantly influence the natural history of HIV/AIDS [18] , it is reasonable to hypothesize that human genetic factors may continue to exert measurable effects after therapy is initiated. The major objective of the present study, therefore, was to investigate the contribution of HLA class I variation to virologic, immunologic, and survival outcomes in a large cohort of HIV-infected, antiretroviral-naive individuals initiating HAART. A secondary objective was to confirm known associations between HLA class I parameters [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] and markers of progression of untreated disease in a pretherapy cross-sectional analysis of the present cohort.
SUBJECTS AND METHODS

Study Subjects: The HAART Observational Medical Evaluation and Research (HOMER) Cohort
In British Columbia, Canada, antiretroviral agents are distributed free of charge to HIV-infected individuals, through a centralized HIV/AIDS drug treatment program [19] . Routine clinical monitoring of patients takes place at ∼3-month intervals, at which time plasma viral loads are determined (by use of the Roche Amplicor Monitor Assay) and CD4 cell counts are performed. Note that the ultrasensitive adaptation to the Roche viral load assay was not routinely available over the course of the study; for this reason, a constant lower assay limit of !500 HIV RNA copies/mL was used. The HOMER cohort is an open, treatment-based cohort that includes all HIV-infected, antiretroviral-naive adults у18 years of age who have initiated HAART through the treatment program since August 1996 [19] . A subset of the HOMER cohort, comprising all HIVinfected individuals who initiated triple therapy (consisting of 2 nucleoside reverse-transcriptase inhibitors and either a protease inhibitor or a nonnucleoside reverse-transcriptase inhibitor) in British Columbia between August 1996 and September 1999 ( ) has been described elsewhere [20] [21] [22] . The n p 1191 present study population represents a nonrandom subset of 765 of these 1191 subjects who were included in the current study on the basis of the availability of a blood sample for HLA typing. In the HOMER cohort, ∼97% of subjects have HIV-1 subtype B infections [23] . Ethical approval was obtained through the institutional ethics review board.
HLA Typing
HLA class I typing was performed on DNA extracted from blood by use of a validated "in-house" sequence-based typing procedure based on International Histocompatibility Working Group protocols. This procedure involves independent, locusspecific, nested polymerase chain reaction amplification of exons 2 and 3 of HLA-A, -B, and -C, followed by automated, bidirectional DNA sequencing. Allele interpretation was performed by comparing sequence data against all alleles in the ImMunoGeneTics (IMGT) HLA database [24] as of August 2005. Four-digit resolution was achieved for all specific alleles investigated in the present study (e.g., B*5701 and B*35P[x]). Where possible, ambiguous allele combinations were resolved through incorporation of known allele frequencies and/or haplotypes [25] . Homozygous combinations were defined as combinations exhibiting no nucleotide mixtures over exons 2 and 3 for each individual class I locus.
Statistical Analyses
Associations between HLA types and pretherapy HIV clinical parameters. For each subject, a single baseline viral load and CD4 cell count (representing the most recently collected measurement within the 180 days before initiation of HAART) was used as a clinical marker of HIV clinical status before treatment; 90% of viral load and CD4 cell measurements at baseline were collected in the 90 days preceding initiation of therapy. Associations between HLA parameters (including allele frequencies, zygosity, and possession of specific alleles) and pretherapy viral load and CD4 cell count were investigated using 1-way analysis of variance (ANOVA), as well as the Wilcoxon rank sum and Kruskal-Wallis tests.
Longitudinal analysis of the influence of HLA parameters on post-HAART outcomes. Associations between HLA types and post-HAART outcomes were investigated using KaplanMeier survival analysis and Cox proportional hazards regression. Virologic and immunologic end points were defined as follows: time to viral suppression was defined as the time elapsed between initiation of HAART and the time when the first of at least 2 consecutive viral loads of !500 HIV RNA copies/mL was achieved. Time to a CD4 cell count increase of 1100 cells/mm 3 was defined as the time elapsed between initiation of HAART and the time when the first of at least 2 consecutive CD4 cell counts 1100 cells/mm 3 above the baseline count was achieved. Event-free subjects were censored on the date when the last viral load or CD4 cell count was determined up to the study's end date of 30 September 2004. Deaths occurring to 30 September 2004 were identified through linkage with the British Columbia Department of Vital Statistics and were classified according to the International Classification of Diseases, 10th Revision. All nonaccidental deaths were considered to be potentially HIV related and were considered to be Figure 1 . A, Associations between HLA zygosity and the pretherapy plasma HIV RNA load. Diamonds and lines denote medians and interquartile ranges, respectively. The no. of subjects in each group (n) is shown below the graphs. Note that the different total n values for the "HLA-C" and "Any" categories reflect the fact that complete HLA-C types were available for only 706 of 765 subjects. B, Associations between HLA class I allele frequencies and the pretherapy HIV RNA load. Each subject was assigned an "HLA frequency score" reflecting the sum of their HLA allele frequencies at each locus. HLA frequency scores were stratified into quartiles, where a "rare" score denoted the first (i.e., lowest) quartile, a score "medium" denoted the second and third quartiles, and a "common" score denoted the fourth (i.e., uppermost) quartile. Diamonds and thin lines denote medians and interquartile ranges, respectively. The n values for each group are shown below the graphs. Note that different total n values for the "HLA-C" and "Any" categories reflect the fact that complete HLA-C types were available for only 706 of 765 subjects.
"events" in the survival analysis. Accidental deaths were considered to be nonevents, and subjects were censored at the date of death. The median length of follow-up was 5.8 years.
Cox proportional hazards regression was used to calculate univariate and multivariate hazard ratios (HRs) and 95% confidence intervals (CIs) for each end point. Baseline variables that were modeled were sex (male vs. female [reference group]), age (per 10-year increment), AIDS diagnosis (yes vs. no), plasma HIV RNA load (per log 10 increment), CD4 cell count (per decrement of 100 cells/mm 3 ), adherence to therapy during the first year after initiation (у95% adherent vs. !95% adherent) [24] , type of therapy received at treatment initiation (therapy containing a protease inhibitor vs. therapy containing a nonnucleoside reverse-transcriptase inhibitor), history of injection drug use (yes vs. no), CCR5D32 genotype (D32/wt vs. wt/wt) [21] , and HIV coreceptor phenotype (R5/X4 vs. R5) [20] . Variables for which in univariate analyses were in-P ! .1 cluded in multivariate analyses. All tests of significance were 2-sided, with denoting statistical significance. Statistical P ! .05 analyses were performed using SAS software (version 8.0; SAS Institute).
RESULTS
Study Population
Subjects represent a subset (64%) of the total population of all ( ) treatment-naive adults who initiated triple-comn p 1191 bination therapy in the province of British Columbia, Canada, between August 1996 and September 1999 and who were selected on the basis of the availability of a blood sample for HLA typing. Comparison of the pretherapy characteristics of subjects included in ( ) and excluded from ( ) n p 765 n p 426 the study reveals no significant differences in the pretherapy CD4 cell count (median, 280 cells/mm 3 ). However, subjects who were included in the study had a slightly lower pretherapy viral load (median HIV RNA load, 5.07 vs. 5.15 log 10 copies/ mL; ); were, on average, older (median age, 37.2 vs. P p .03 36.5 years;
); and were more likely to be male (per-P p .02 centage of subjects who were male, 88% vs. 77%; ) P ! .0001 than were subjects who were excluded from the study. HLA-A and HLA-B typing was completed for all 765 subjects, whereas HLA-C types were determined for 706 subjects. Although complete data on ethnicity are unavailable, the HLA allele frequencies noted were consistent with those expected in a predominantly North American white population.
Associations between HLA Types and Pretherapy Clinical Parameters
HLA zygosity effects. Homozygosity at any class I locus was associated with a significantly higher pretherapy viral load (median, 5.11 vs. 5.04 log 10 HIV RNA copies/mL in subjects homozygous at any locus vs. subjects heterozygous at all loci; ) (figure 1A). No additional effect was observed when P p .03 homozygosity at у2 loci was investigated (not shown). When class I loci were considered individually, HLA-C homozygosity was significantly associated with a higher pretherapy viral load ( ), and a trend was observed between HLA-B homo-P p .03 zygosity and a higher viral load ( ) (figure 1A). Note P p .08 that the results of analysis of the independent loci remained consistent in a secondary analysis that excluded individuals who were homozygous at multiple loci (data not shown). No association between HLA zygosity and pretherapy CD4 cell counts was observed (median CD4 cell count, 290 vs. 280 cells/mm 3 in homozygous vs. heterozygous subjects, respectively;
). P p .9 HLA frequency-dependent effects. Each subject was assigned a total of 4 "HLA frequency scores" reflecting the sum of cohort allele frequencies at each individual class I locus, as well the sum of allele frequencies across combined loci. Scores were stratified into the following categories: "rare" (first quartile), "medium" (second and third quartiles), and "common" (fourth quartile). Having rare HLA-B (but not HLA-A or HLA-C) alleles was significantly associated with a lower pretherapy viral load (5.04 vs. 5.11 log 10 HIV RNA copies/mL among subjects with rare versus common alleles, respectively; ) P p .01 ( figure 1B) . Similarly, a combined rare score was also associated with a lower pretherapy viral load ( ) ( figure 1B ). P p .01 HLA class I locus-specific and allele-specific effects. The pretherapy viral load varied significantly with specific HLA-B alleles ( , 1-way ANOVA) (figure 2) but not with HLA-P p .02 A or HLA-C alleles (
[not shown]). HLA-B*5701 was P 1 .1 associated with a lower pretherapy viral load (median, 4.6 vs. 5.1 log 10 HIV RNA copies/mL for B*5701-positive vs. B*5701-negative subjects, respectively;
), whereas HLA-B*55 P ! .001 was associated with a higher pretherapy viral load (median, 5.4 vs. 5.0 log 10 HIV RNA copies/mL for B*55-positive vs. B*55-negative subjects, respectively;
). Possession of HLA-P p .017 B*13 and B*42 alleles was also associated with a lower pretherapy viral load ( ). Of note, when the HLA-B*35-P ! .05 positive group was subdivided into HLA-B*35P(x)-positive and HLA-B*35P(y)-positive groups [17] , no significant differences in the viral load at baseline were observed ( ). Analysis P p .4 of HLA frequency-dependent and allele-specific associations with pretherapy CD4 cell counts revealed similar trends, although associations generally did not achieve statistical significance (not shown).
Effects of HLA Class I Genetic Parameters on Clinical Outcomes and Survival after Initiation of HAART
Effects of HLA class I parameters on survival after initiation of HAART. Over a median follow-up of 5.8 years, 119 deaths were recorded among 765 subjects, for a crude mortality rate of 15.6%. All nonaccidental deaths ( [80.7%]) were conn p 96 sidered to be potentially HIV related and were classified as events in the survival analysis (note that, for 69 [71.9%] of these 96 nonaccidental deaths, HIV and/or AIDS was specified as the underlying cause; the next most common causes of death were cardiovascular disease [ {11.4%}] and cancers [n n p 11 p 5 {5.2%}]). Accidental deaths ( [19.3%] , the majority n p 23 of which were due to overdoses) were censored on the date of death.
In univariate analyses, we observed no statistically significant association between homozygosity at any class I locus and time to nonaccidental death after initiation of HAART (HR, 0.83 [95% CI, 0.54-1.28], for homozygous vs. heterozygous subjects; ) (figure 3 and table 1) . Similarly, post-HAART survival P p .4 did not differ significantly according to HLA frequency score (HR, 1.03 [95% CI, 0.59-1.80], for subjects with rare scores vs. the reference group with common scores; ) (figure 3 P p .9 and table 1).
We investigated whether specific HLA alleles that were previously associated with differential rates of progression of untreated disease may also be associated with survival times after initiation of HAART. Of interest, possession of HLA-B*5701 was associated with a trend toward an increased risk of nonaccidental death after HAART initiation; however, this trend did not reach statistical significance (HR,
). Possession of B*27, B*35P(x), or B22 serogroup P p .2 alleles was not significantly associated with post-HAART survival times, although trends were observed toward improved survival among B*27-positive subjects and poorer survival among B22 serogroup-positive subjects ( , for all) (figure 3 and
Effects of HLA class I parameters on virologic and immunologic responses to HAART. We investigated whether HLA class I parameters were associated with initial virologic and immunologic responses to HAART, as defined by "time to achieve suppression of the viral load to !500 HIV RNA copies/ mL" and "time to achieve an increase in the CD4 cell count to 1100 cells/mm 3 above baseline," respectively. Most (657 [85.9%] of 765) subjects achieved suppression of the viral load to !500 HIV RNA copies/mL; of these subjects, 522 (79.5%) achieved suppression within 1 year after HAART initiation. A total of 576 (75.3%) of 765 subjects achieved an increase in the CD4 cell count to 1100 cells/mm 3 above the baseline count; of these subjects, 336 (58.3%) achieved this increase within 1 year of HAART initiation.
In univariate analyses, we observed no significant association between HLA zygosity and time to virologic suppression (HR, 0.98 [95% CI, 0.83-1.15] for homozygous vs. heterozygous subjects;
). In univariate analyses, a trend toward a longer P p .8 time to achieve an increase of 1100 cells/mm 3 in the CD4 cell count was observed for homozygous subjects (HR, 0.84 [95% CI, 0.71-1.00];
). In multivariate analyses adjusting for P p .053 demographic variables, clinical variables, adherence [26] , and other host [21] and viral [20] ), compared with that noted for subjects with P p .03 common allele scores. This finding remained significant in multivariate analyses adjusting for demographic, clinical, and genetic variables at baseline (table 2) . In univariate analyses, no significant association between HLA allele frequency scores and the CD4 cell response after HAART initiation was observed, although a trend toward a poorer immunologic response among subjects with rare allele scores was observed (table 3) .
The HLA-B*5701, HLA-B*27, and B22 serogroup alleles were not significantly associated with differential short-term virologic or immunologic responses after HAART initiation (P 1 , univariate analysis) (tables 2 and 3). In univariate analysis, .1 possession of B*35P(x) was associated with a more rapid time to virologic suppression to !500 HIV RNA copies/mL (table  2) ; however, this association did not remain significant in multivariate analyses adjusting for parameters at baseline (HR, 1.23 [95% CI, 0.87-1.75];
). No significant association be-P p .2 tween B*35P(x) and initial CD4 cell response was observed (table 3) .
Secondary exploratory analyses. Results of exploratory analyses restricted to individuals infected with HIV-1 subtype B (∼97% of subjects) and individuals whose baseline CD4 cell count and viral load were measured in the 90 days preceding HAART initiation (∼90% of subjects) were consistent with the results of the original analysis.
DISCUSSION
Associations between HLA genetic parameters and the status of untreated HIV disease were investigated using the pretherapy cross-section of the cohort in the present study. The observation that homozygosity at any class I locus was associated with a higher pretherapy viral load in our cohort is consistent with the reported "homozygous disadvantage" effect on rates of HIV disease progression observed in historic seroconverter cohort studies [10, 11] , and it suggests that this effect is strong enough Figure 3 . A-F, Impact of HLA zygosity-dependent, allele frequency-dependent, and specific allele effects on the time to nonaccidental death after initiation of highly active antiretroviral therapy. +, positive; Ϫ, negative.
to be observed even in cross-sectional analyses of chronically infected individuals with unknown lengths of infection. Similarly, the observation that possession of rare alleles at the HLA-B (but not HLA-A or HLA-C) locus is associated with a lower pretherapy viral load supports frequency-dependent effects of class I alleles on untreated HIV disease [12, 13] , and it suggests that the dominant locus driving this phenomenon is HLA-B [15] . Furthermore, the observation that the pretherapy viral load varied significantly according to possession of specific HLA-B (but not HLA-A or HLA-C) alleles is consistent with results from an independent analysis of chronically infected individuals that reported a profound influence of HLA-B on 
NOTE.
The n values denote the no. of subjects in each group. The total n values for frequency-and zygosity-dependent effects do not total 765, because some subjects were missing data on HLA-C. CI, confidence interval; HR, hazard ratio; IDU, injection drug use.
a HRs 11 denote a more rapid time to nonaccidental death after initiation of HAART, whereas HRs !1 denote a slower time to nonaccidental death after initiation of HAART (relative to indicated comparison group). b Each subject was assigned an HLA frequency score reflecting the sum of allele frequencies across combined loci, and scores were stratified into the following categories: "rare" (first quartile), "medium" (second and third quartiles), and "common" (fourth quartile immune containment of HIV infection as estimated by viral load [15] . Finally, results suggest that the protective effects of HLA-B*5701 [4, 16] and the detrimental effects associated with B22 serogroup alleles [5] also persist into chronic infection (as evidenced by differences in pretherapy viral loads in these subjects). Of interest, no significant association was observed between HLA-B*27 and HLA-B*35P(x) alleles on pretherapy viral loads in the present study, in contrast to previous studies reporting protective [4] and detrimental [17] effects, respectively, of these alleles on rates of HIV disease progression.
Despite numerous statistically significant associations observed between HLA and pretherapy viral loads, it is important to note the limitations of this analysis. First, the cross-section of our cohort at baseline represents individuals in varying stages of chronic infection. HLA genotypes previously associated with rates of HIV disease progression in studies of seroconverter cohorts [4, 5, [10] [11] [12] or acute infection [3] may not necessarily be observed in the present cross-sectional analysis of pretherapy clinical parameters. In addition, no consistent significant associations were observed between HLA and pretherapy CD4 cell counts. This observation may partially be explained by the fact that this is an HIV treatment cohort, with individuals enrolled in the cohort at therapy initiation. Because the guidelines for HAART initiation are largely CD4 cell driven, a pretherapy cross-sectional analysis may underestimate associations between HLA and the CD4 cell count (and, to a lesser extent, Table 2 . Associations between HLA class I genetic parameters (and other baseline variables) and time to suppression of the viral load to !500 HIV RNA copies/mL after initiation of highly active antiretroviral therapy (HAART). 
a HRs 11 denote a more rapid time to suppression of the viral load to !500 HIV RNA copies/mL after initiation of HAART, whereas
HRs !1 denote a slower time to viral load suppression after initiation of HAART (relative to indicated group comparison). b Each subject was assigned an HLA frequency score reflecting the sum of allele frequencies across combined loci, and scores were stratified into the following categories: "rare" (first quartile), "medium" (second and third quartiles), and "common" (fourth quartile the viral load). Despite these limitations, we were able to detect HLA frequency-dependent and allele-specific effects on HIV clinical parameters consistent with those noted in previous reports [3] [4] [5] [6] [7] [8] [9] , suggesting that the effects of HLA class I on untreated HIV disease are substantial and persist into chronic infection.
The analysis of an HIV treatment cohort, however, is ideal for the investigation of the influence of HLA genetics on HAART outcomes. Although there is much evidence supporting the effects of HLA class I on rates of progression of untreated HIV disease [4, 5, [10] [11] [12] , it is not known whether class I variation may still exert an effect on viral load responses, immunologic reconstitution, and/or survival once therapy is initiated. Overall, we observed no significant effects of HLA zygosity-dependent or frequency-dependent effects on survival in the 15-year period after initiation of HAART, suggesting that these parameters do not influence survival after therapy initiation.
In an analysis of specific alleles, we observed a very weak trend toward improved survival among B*27-positive subjects and poorer survival among B22 serogroup-positive subjects; however, these results did not achieve statistical significance ( ). Despite strong evidence identifying HLA-B35P(x) as P 1 .1 a risk factor for disease progression in persons with untreated HIV infection [17] , no association between B35P(x) and sur- 
a HRs 11 denote a more rapid time to an increase in the CD4 cell count of 1100 cells/mm 3 after initiation of HAART, whereas HRs !1 denote a slower time to an increase in the CD4 cell count of 1100 cells/mm 3 after initiation of HAART (relative to indicated comparison group).
b Each subject was assigned an HLA frequency score reflecting the sum of allele frequencies across combined loci, and scores were stratified into the following categories: "rare" (first quartile), "medium" (second and third quartiles), and "common" (fourth quartile vival after HAART was observed in the present study. Given the identification of HLA-B*5701 as a risk factor for the lifethreatening abacavir hypersensitivity reaction [27, 28] , it was interesting to note that HLA-B*5701 was associated with a weak trend toward poorer survival after HAART. Abacavir hypersensitivity was unlikely to explain this result, however. Of the 9 nonaccidental deaths of B*5701-positive subjects, only 2 involved subjects who had been prescribed abacavir (and abacavir prescription was not temporally correlated with death in either case). Alternatively, results may be attributable to a survivor bias where B*5701-positive subjects initiating therapy represent individuals who have been infected with HIV for a longer period (a hypothesis that we are unable to investigate, because dates of seroconversion are unknown). However, it should be noted that B*5701-positive individuals were not significantly older than B*5701-negative individuals in this cohort (data not shown).
Overall, results suggest that these specific HLA-B alleles do not significantly influence 5-year survival rates after HAART initiation. However, it is important to note that the numbers of observed events were small and, thus, larger cohorts and/or longer follow-up times may be necessary to detect effects, if present. As expected, the factors most strongly associated with survival after HAART were younger age, a higher CD4 cell count at baseline, and treatment adherence. In addition, we wished to investigate whether HLA genetic parameters may influence shorter-term HAART outcomesnamely, the ability to achieve virologic suppression and/or immune reconstitution (as measured by an increase in the CD4 cell count) after initiation of therapy. In multivariate analyses, we observed a significant association between homozygosity at any class I locus and a poorer CD4 cell response after initiation of HAART, suggesting that the HLA "homozygous disadvantage" [10, 11] may persist even after initiation of therapy. Unfortunately, we were not able to address a recently reported association between the HLA*A1-B8-DR3-DQ2 haplotype and improved immunologic reconstitution after HAART [29] , because neither haplotype analysis nor class II typing was performed in the current study.
Of interest, we observed a significantly increased time to virologic suppression in individuals with rare HLA alleles, compared with individuals with common HLA alleles, despite the fact that rare allele scores were associated with a lower pretherapy viral load. A weak trend toward a poorer immunologic response to HAART was also observed among individuals in this group. These associations remained significant in an analysis restricted to subjects with HIV-1 subtype B infections, suggesting that this result cannot be explained by individuals who possess HLA alleles that are uncommon in North America and who harbor non-subtype B infections that may not respond as readily to HAART. Finally, to date, the strongest evidence supporting a role for HLA in the context of HAART outcomes relates to the association between HLA-B*5701 and class II allele DRB1*0101 and immune-mediated hypersensitivity reactions to abacavir [27, 28] and nevirapine [30] , respectively. Because data on adverse events are incompletely available (and because class II typing was not performed), we were unable to investigate comprehensively associations between HLA and antiretroviral-associated hypersensitivity reactions in this cohort.
In conclusion, results from our cross-sectional pretherapy analysis suggest that previously characterized effects of HLA class I (including zygosity-dependent, frequency-dependent, and specific effects of HLA-B*5701) on untreated HIV disease may persist well into chronic untreated infection. HLA class I zygosity-and frequency-dependent effects may influence shortterm immunologic and virologic HAART outcomes, respectively, and thus deserve further investigation in independent cohorts. Results do not support a significant continued influence of HLA class I zygosity-or frequency-dependent effects on survival in the 5-year period after initiation of HAART; however, results do not exclude a potential effect of HLA on survival in the longer term.
